Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses hormonal therapies for acne related to endocrine disorders and provides practical guidelines for managing hormonally influenced acne in clinical practice, but reports no new clinical results.

Women with severe acne, hirsutism, and androgenic alopecia often have higher levels of certain androgens, but the specific pattern can't be predicted just by looking at symptoms.

Lower testosterone levels in men may be linked to a higher risk of severe coronary artery disease.

This study found that early-onset male androgenetic alopecia was associated with a higher prevalence of metabolic syndrome compared to age-matched controls.

This study found that SZ95 sebocytes and HaCaT keratinocytes exhibit distinct enzyme expressions and activities, implicating their different roles in androgen metabolism and homeostasis in vitro.

This review examines testosterone's role in male health and aging but reports no new clinical results; the authors highlight the need for further research on optimal testosterone levels to prevent age-related conditions.

In this study, women with PCOS had a higher prevalence of hepatic steatosis compared to controls, with associated metabolic issues like insulin resistance and metabolic syndrome.

In this study, the prevalence of polycystic ovary syndrome among women seeking primary healthcare in Salvador, Brazil, was found to be 8.5% using the Rotterdam criteria.

This case study reports that a virilizing Leydig cell type ovarian tumor in a 40-year-old woman caused hyperandrogenism and virilization symptoms, which improved post-surgery.

In this study, testosterone was reported to increase aquaporin levels and water reabsorption in the kidneys of male rats, potentially leading to higher blood pressure, with effects mitigated by flutamide and finasteride.

This study found that among different subtypes of PCOS based on Rotterdam criteria, group A showed higher androgen levels and hirsutism, while all subtypes had increased LH and LH/FSH compared to controls.

This case report describes a 57-year-old woman with hirsutism, hair loss, and vocal changes, who was found to have elevated testosterone levels but normal dehydroepiandrosterone sulfate levels.

This case report details a postmenopausal woman with hyperandrogenism due to both adrenal adenoma and ovarian hyperthecosis, highlighting the effectiveness of hormonal suppression and venous sampling for diagnosis.

In this study of women aged 18-45 from an endocrine referral group, researchers found that while clinical hirsutism severity is independently associated with biochemical hyperandrogenism, the relationship is modest and suggests different biological aspects are at play.

This review discusses existing literature on the effects of isoflavone in alleviating PCOS symptoms, highlighting its potential benefits in reducing testosterone levels, improving metabolic profiles, and lowering inflammation and oxidative stress, although findings have been both significant and non-significant.

This report describes a complex case of postmenopausal hyperandrogenism with virilization and concurrent rare ovarian tumors, highlighting the critical role of interdisciplinary collaboration in diagnosing and managing such challenging scenarios.

This study assessed the nutritional status of emerging adult women with PCOS and found that while their body measurements were higher than standard, their mean biochemical parameters were within the normal range.

This study found that women with hirsutism in the Amassoma metropolis had higher levels of testosterone, cholesterol, and glucose compared to non-bearded women.

This case report describes a 48-year-old woman with a history of PCOS and chemotherapy-induced menopause who was found to have a rare ovarian steroid cell tumor causing postmenopausal hyperandrogenism.

The document concludes that understanding health requires considering evolutionary perspectives on reproductive fitness, and recognizing the complexity of factors like diet, testosterone, and sexual orientation.

The authors updated recommendations on diagnosing and treating women's sexual dysfunctions, emphasizing a comprehensive assessment approach, while noting the need for further multidisciplinary research.

This meta-analysis reported a significant association between polycystic ovary syndrome and an increased risk of obstructive sleep apnea in adult patients.

This review discusses potential mechanisms contributing to higher COVID-19 mortality among men, particularly the roles of smoking, genetic factors, and reproductive hormones, without presenting new clinical findings.

This review discusses the influence of androgens on hair and sebaceous growth, emphasizing that response may depend more on peripheral sensitivity than on hormone levels; it reports no new empirical results.

This study found that women with polycystic ovary syndrome in the UK show significant differences in phenotypic and metabolic characteristics based on ethnicity, age, and obesity, influencing management strategies.

This review presents substantial evidence supporting testosterone use for hypoactive sexual desire disorder in postmenopausal women, but notes safety concerns with off-label prescribing due to lack of approved formulations.

This guideline provides evidence-based recommendations for prescribing testosterone therapy to women with hypoactive sexual desire disorder, noting a moderate therapeutic benefit but highlighting limited data and regulatory challenges.

This study found no general elevation in androgen levels among men predisposed to balding, despite a correlation with the free-to-total testosterone ratio; no link was observed with acne.

This study provides a guideline for the safe and effective use of testosterone in women with hypoactive sexual desire disorder, recommending systemic transdermal testosterone for appropriate candidates while highlighting the importance of informed consent and monitoring due to unestablished long-term safety.

This review discusses the controversial cardiovascular safety and efficacy of subcutaneous testosterone therapy in postmenopausal women, noting that its long-term use appears safe, but CV risk assessments remain disputed.